过敏性鼻炎放大慢性鼻窦炎患者的哮喘风险:大规模回顾性队列分析
基于TriNetX美国协作网络电子健康记录,纳入2009至2019年成人慢性鼻窦炎(CRS)患者并与无CRS对照比较,另比较CRS合并过敏性鼻炎(AR)与单纯CRS。倾向评分匹配后,CRS与新发哮喘(aRR=1.42,95%CI 1.36-1.48)和哮喘急性加重(aRR=1.87,95%CI 1.75-2.00)风险升高相关,合并AR进一步放大风险。
要点
- CRS患者1年新发哮喘风险aRR=1.42,哮喘急性加重风险aRR=1.87。
- CRS合并AR者较单纯CRS新发哮喘风险1年aRR=1.69、2年1.65、5年1.58。
- CRS合并AR者哮喘急性加重风险在所有时间点均增加逾一倍。
核心结论
- CRS与新发哮喘及后续哮喘急性加重风险升高相关。
- 合并AR可识别CRS中哮喘风险更高的表型。
研究设计与样本
- 回顾性队列研究,使用TriNetX美国协作网络电子健康记录平台,覆盖超过1亿患者。
- 第二分析比较CRS合并AR患者与单纯CRS患者。
- 补充分析以慢性鼻窦炎伴鼻息肉(CRSwNP)替代CRS。
- 采用倾向评分匹配平衡人口学特征和合并症。
主要发现
- 匹配后,CRS患者1年新发哮喘风险高于无CRS对照(aRR=1.42,95%CI 1.36-1.48)。
- CRS患者1年哮喘急性加重风险高于对照(aRR=1.87,95%CI 1.75-2.00),2年和5年趋势相似。
- CRS合并AR者1年新发哮喘风险高于单纯CRS(aRR=1.69,95%CI 1.65-1.73)。
- CRS合并AR者2年新发哮喘风险aRR=1.65(95%CI 1.62-1.68),5年aRR=1.58(95%CI 1.56-1.60)。
- CRS合并AR者所有时间点哮喘急性加重风险增加逾一倍。
临床怎么用
- 对CRS患者应评估哮喘风险,合并AR者需警惕更高风险表型。
- 需开展表型导向研究以确定靶向上气道管理能否减轻下游哮喘负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) are two highly prevalent airway diseases in the United States. While the coexistence of CRS and asthma is well recognized, less is known about the development of new-onset asthma in CRS, particularly in the context of comorbid AR. This study assessed the impact of CRS and AR on incident asthma using a large electronic health record (EHR) database. METHODS: We conducted a retrospective cohort study using the TriNetX US Collaborative Network, a federated EHR platform encompassing over 100 million patients. Adults ≥ 18 years between January 2009 and December 2019 with CRS were compared to controls without CRS. A second analysis compared patients with CRS and concurrent AR to those with CRS alone. Supplemental analyses substituted chronic rhinosinusitis with nasal polyps (CRSwNP) for CRS. Propensity score matching balanced cohorts on demographics and comorbidities. Primary outcomes were new-onset asthma and asthma exacerbations, assessed at 1, 2, and 5 years. RESULTS: After matching, pre-existing CRS was associated with higher risk of new-onset asthma (adjusted relative risk [aRR] = 1.42, 95% CI 1.36-1.48) and exacerbations (aRR = 1.87, 95% CI 1.75-2.00) at 1 year versus CRS controls, with similar trends at 2 and 5 years. Coexisting AR further amplified risk: patients with CRS + AR had increased asthma incidence relative to CRS alone at 1 year (aRR = 1.69, 95% CI 1.65-1.73), 2 years (aRR = 1.65, 95% CI 1.62-1.68), and 5 years (aRR = 1.58, 95% CI 1.56-1.60), with more than doubled exacerbation risk across all time points. Directionally similar findings were observed in CRSwNP analyses. CONCLUSIONS: CRS is associated with increased risk of incident asthma and subsequent exacerbations, and coexisting AR identifies a higher-risk phenotype within CRS. These findings highlight the need for phenotype-informed studies to determine whether targeted upper-airway management can mitigate downstream asthma burden.
引用
- Lee AJ, Chaaban MR. Allergic Rhinitis Amplifies Asthma Risk in Patients With Chronic Rhinosinusitis: A Large-Scale Retrospective Cohort Analysis. Int Forum Allergy Rhinol. 2026. PMID: 41830158. doi:10.1002/alr.70141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。